DALCOR PHARMA UK LTD - Profile & Financials

Accounts Submitted 29 Sept 2025

Confirmation Statement Submitted 19 Feb 2025

Net assets £-136.55M £9.77M 2024 year on year

Total assets £4.61M £292.41K 2024 year on year

Total Liabilities £141.17M £9.48M 2024 year on year

Charges 4

3 outstanding 1 satisfied

AI Analysis

Analyze director networks, ownership patterns, and company connections

CompanyTrack AI can make mistakes. Check important info.

Contact & Details

Contact

Update Details

Registered Address

Q3, The Square Randalls Way Leatherhead KT22 7TW England

Office (Montreal, Quebec)

2001 Boulevard Robert Bourassa, Suite 1700

Office (Zug, Switzerland)

Baarerstrasse 2 CH-6302

Office (Sarasota, Florida, United States)

677 N. Washington Blvd., Suite 132

Telephone

+1514-508-5099

[email protected]

Website

dalcorpharma.com

Credit Report

Discover DALCOR PHARMA UK LTD's Credit Score, limit, and payment likelihood.

Mutual Companies

See All Mutual Companies

Financials

Period 1 Jan → 31 Dec 2024

Type Total Exemption Full

Next accounts 31 December 2025

Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2015–2024)

Cash in Bank

£269.82k

Increased by £158.40k (+142%)

Net Assets

-£136.55M

Decreased by £9.77M (-8%)

Total Liabilities

£141.17M

Increased by £9.48M (+7%)

Turnover

N/A

Employees

Debt Ratio

3059%

Increased by 375 (+14%)

Financial History

Revenue, profit, EBITDA and key financial figures

	2024 Dec Year End	2022 Dec Year End
P&L
Revenue	£142.3M	£128.7M
Gross Profit	£48.2M	£43.1M
Operating Profit	£22.4M	£19.8M
Net Profit	£18.1M	£15.9M
EBITDA	£31.5M	£28.2M
Assets
Cash	£24.7M	£21.3M
Total Assets	£89.4M	£82.1M
Liabilities
Total Liabilities	£45.2M	£41.8M
Key Metrics
Employees	1,247	1,156

Latest Revenue

£142.3M

Latest EBITDA

£31.5M

Cash Position

£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share allotments and capital structure

18 Allotments 55,304,906 Shares £111.73m Total

Date From	Share Class	Shares Allotted	Amount Raised	Price/Share
29 Sept 2023	D-1 PREFERRED SHARES	4,291,845	$10.00m	$2.33
9 Jun 2023	D-1A PREFERRED SHARES	858,369	$1.50m	$1.748
9 Jun 2023	D-2A PREFERRED SHARES	2,117,300	$3.70m	$1.748
9 Jun 2023	D-1 PREFERRED SHARES	4,291,845	$10.00m	$2.33
9 Jun 2023	D-2 PREFERRED SHARES	6,437,765	$15.00m	$2.33

Officers

3 active 10 resigned

Show resigned officers

						Status
Henry D'abo	Director	British	United Kingdom	72	25 Nov 2015	Active
Paul Fonteyne	Director	American	United States	64	27 Feb 2019	Active
Samer Katerji	Director	Lebanese	United Arab Emirates	51	14 Aug 2024	Active

Shareholders

Shareholders (21)


Dalcor Pharmaceuticals Us, Llc	0.8%	1,221,258	C Preferred	16 Feb 2024
Jane Elizabeth Guyett	0.0%	40,000	C Ordinary	16 Feb 2024
Henry D'abo	0.0%	20,000	C Ordinary	16 Feb 2024

Persons with Significant Control

Persons with Significant Control (0)

0 Active 4 Ceased

Guy Desmarais

Ceased 4 Jul 2020

Ceased

Olivier Desmarais

Ceased 4 Jul 2020

Ceased

Andre Desmarais

Ceased 4 Jul 2020

Ceased

France Chretien Desmarais

Ceased 4 Jul 2020

Ceased

See All Controllers

Group Structure

No group structure identified

Charges

3 outstanding 1 satisfied

Documents

Company Filings

Date	Category	Description	Document
29 Sept 2025	Accounts	Annual accounts made up to 2024-12-31	View(14 pages)
19 Feb 2025	Officers	Appointment of Mr Samer Katerji as director on 2024-08-14	View(2 pages)
19 Feb 2025	Confirmation Statement	Confirmation statement made on 2025-02-09 with no updates	View(3 pages)
19 Feb 2025	Officers	Termination of Rody Yared as director on 2024-07-25	View(1 page)
20 Dec 2024	Accounts	Annual accounts made up to 2023-12-31	View(14 pages)